Metraipolis › archive › dc_162dcdb35750
What Are the Potential Therapeutic Benefits of Targeting Blood-Borne Lipoproteins in the Treatment of Alzheimer's Disease? — Europe PMC PMID:42439669
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42439669
- DOI
- 10.3390/cells15131191
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T14:27:40.081Z
- SHA-256 of the archived text
fde89008e3adb900a11faff6a7a00c174833f08ea523f83dcc2f98c87a64dfee- Stable URL of this page
https://metraipolis.com/documento/dc_162dcdb35750
How to cite
What Are the Potential Therapeutic Benefits of Targeting Blood-Borne Lipoproteins in the Treatment of Alzheimer's Disease? — Europe PMC PMID:42439669 — Europe PMC (en), https://europepmc.org/article/MED/42439669 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_162dcdb35750 (Metraipolis archive dc_162dcdb35750, sha256 fde89008e3adb900a11faff6a7a00c174833f08ea523f83dcc2f98c87a64dfee)
BibTeX
@misc{dc162dcdb35750,
title = {What Are the Potential Therapeutic Benefits of Targeting Blood-Borne Lipoproteins in the Treatment of Alzheimer's Disease? — Europe PMC PMID:42439669},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42439669},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_162dcdb35750; sha256 fde89008e3adb900a11faff6a7a00c174833f08ea523f83dcc2f98c87a64dfee},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42439669. Agents can read the archived copy with the MCP tool read_document.